TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15500597

Group type: EXPERIMENTAL
Intervention: Buprenorphine (58 mg subcutaneous depot injection)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11771571

Group type: EXPERIMENTAL
Intervention: Dexibuprofen 400 mg t.i.d.
Number of subjects: 401

Group type: COMPARATOR
Intervention: Dexibuprofen
Number of subjects: 401

Group type: COMPARATOR
Intervention: Racemic ibuprofen 800 mg t.i.d.
Number of subjects: 401

Group type: COMPARATOR
Intervention: Racemic ibuprofen 2400 mg daily
Number of subjects: 401
Study: 9296411

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 381
Study: 8329290

Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 16
Study: 3731904

Group type: EXPERIMENTAL
Intervention: Ventilatory muscle exercise training (VMT) using a prototype, portable device for isocapnic hyperventilation training.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Walking exercise training.
Number of subjects: 18
Study: 29520799

Group type: COMPARATOR
Intervention: Source plasma donation frequency (70 or more donations)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Source plasma donation frequency (1 to 24 donations)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Source plasma donation frequency (highest-frequency donors)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: New donors (control group)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Highest-frequency donors (control group)
Number of subjects: 1254
Study: 27258806

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combined exercise (aerobic + resistance)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 24609465

Group type: EXPERIMENTAL
Intervention: Cued approach training (auditory cue with simple motor response)
Number of subjects: 0
Study: 22611313

Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (32 g/d for 12 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Casein supplementation (control group, 32 g/d for 12 weeks)
Number of subjects: 160
Study: 20923082

Group type: EXPERIMENTAL
Intervention: Odor recognition when participants judged the odor to fit the imagined episode
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Odor recognition with unpleasant odor incongruously paired with a warm episode
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Odor recognition when narrative outlines described familiar characters
Number of subjects: 32
Study: 19022964

Group type: EXPERIMENTAL
Intervention: High-fat diet (40-45 en% fat)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Low-fat diet (20-25 en% fat)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Postprandial RLP-C
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Fasting RLP-C
Number of subjects: 613
Study: 16910917

Group type: EXPERIMENTAL
Intervention: Bio-Oss (3 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bio-Oss (6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (pre-existing subantral bone)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison between group A (3 months) and group B (6 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VEGF expression (group A vs group B)
Number of subjects: 20
Study: 15030306

Group type: EXPERIMENTAL
Intervention: Shigella infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proinflammatory mediators production
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive immune response
Number of subjects: 0
Study: 11114678

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) dietary intake from D0 to D15
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) dietary intake from D0 to W37
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Linolenic acid (LA) dietary intake from D0 to D15
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Linolenic acid (LA) dietary intake from D0 to W37
Number of subjects: 45
Study: 8857632

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) 5-mg patch per day over 3 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study: 8501145

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-glucose meal
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo meal
Number of subjects: 11
Study: 3330182

Group type: EXPERIMENTAL
Intervention: Sublingual prazepam
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral prazepam
Number of subjects: 5
Study: 28499696

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200mg/day)
Number of subjects: 102
Study: 27716293

Group type: COMPARATOR
Intervention: TNT009, a humanized monoclonal antibody directed against the C1s subunit of human complement component C1, administered in a double-blind, randomized, placebo-controlled manner.
Number of subjects: 1
Study: 24302706

Group type: EXPERIMENTAL
Intervention: Multidimensional Health Assessment Questionnaire (MDHAQ)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Multinomial logistic regression
Number of subjects: 980
Study: 22882646

Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) 400 mg/TID and Amoxicillin (AMX) 500 mg/TID for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30
Study: 20073214

Group type: EXPERIMENTAL
Intervention: Chinese medicinal massage for 20 min once every other day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hormone replacement therapy with Premarin 0.625 g, once daily by oral taking
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chinese medicinal massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hormone replacement therapy
Number of subjects: 60
Study: 18085903

Group type: EXPERIMENTAL
Intervention: Implementation intention induction embedded in the questionnaire
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (no implementation intention induction)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Implementation intention induction among participants who returned the questionnaire
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (no implementation intention induction) among participants who returned the questionnaire
Number of subjects: 390
Study: 15636449

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 116
Study: 12171079

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9020242

Group type: EXPERIMENTAL
Intervention: Low-fat diet supplemented with monounsaturated fat
Number of subjects: 24

Group type: COMPARATOR
Intervention: Very-low-fat diet
Number of subjects: 24
Study: 8182900

Group type: EXPERIMENTAL
Intervention: Fluconazole (FLCZ) administered intravenously at a dosage of 3 mg/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Fluconazole (FLCZ) administered orally
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Fluconazole (FLCZ) administered intravenously
Number of subjects: 4
Study: 3235820

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at several doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30081730

Group type: EXPERIMENTAL
Intervention: Arabin cervical pessary and progesterone
Number of subjects: 217
Study: 29291549

Group type: EXPERIMENTAL
Intervention: Therapist-delivered brief intervention with booster
Number of subjects: 780

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC-ED)
Number of subjects: 780
Study: 26558293

Group type: EXPERIMENTAL
Intervention: Stem cell therapy (mesenchymal stem cells and neural fetal stem cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24716671

Group type: EXPERIMENTAL
Intervention: Fontan procedure patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 25
Study: 23725917

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (600 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20642205

Group type: EXPERIMENTAL
Intervention: 1.5% bepotastine besilate ophthalmic solution
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 18377661

Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis-only
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis/Irvingia gabonensis combination
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 16360618

Group type: EXPERIMENTAL
Intervention: Reduced variety condition (limited snack food intake to one chosen snack food)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (limited snack food intake to <1 serving/day with no variety limit)
Number of subjects: 30
Study: 14696884

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined regimen of acetazolamide and dexamethasone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acclimatised group (20 subjects)
Number of subjects: 44
Study: 10999797

Group type: EXPERIMENTAL
Intervention: Arg109 homozygotes
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Arg223 homozygotes
Number of subjects: 284

Group type: COMPARATOR
Intervention: Lys109 homozygotes
Number of subjects: 284

Group type: COMPARATOR
Intervention: Men with blood pressure >= 140/90 mm Hg
Number of subjects: 284
Study: 8788355

Group type: EXPERIMENTAL
Intervention: Educational group (four 40-min sessions)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Psychological intervention group (four 40-min sessions by a psychologist)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (pre- and post-testing only)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Psychological intervention group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Educational group
Number of subjects: 123
Study: 1354085

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 6380564

Group type: EXPERIMENTAL
Intervention: Cervical cerclage (n = 96)
Number of subjects: 194

Group type: COMPARATOR
Intervention: No cervical cerclage (n = 98)
Number of subjects: 194
Study: 31025274

Group type: EXPERIMENTAL
Intervention: Combination therapy (anti-PD-1 and anti-CXCR4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-PD-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-CXCR4
Number of subjects: 0
Study: 30341023

Group type: EXPERIMENTAL
Intervention: Acupuncture focused on the points in the pudendal nerve distribution area (Group 1a)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acupuncture focused on traditional (distal) meridian points (Group 1b)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard care group (Group 2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acupuncture (both Group 1a and Group 1b)
Number of subjects: 51
Study: 27101379

Group type: EXPERIMENTAL
Intervention: Intervention arm with Village Health Teams (VHTs) conducting two prenatal and one postnatal home visit, and mobile phone consultations with health workers.
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Intervention arm with VHTs conducting home visits and consultations.
Number of subjects: 1385
Study: 24504098

Group type: COMPARATOR
Intervention: Aganirsen (0.86 mg/g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aganirsen (1.72 mg/g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aganirsen
Number of subjects: 12
Study: 22873635

Group type: EXPERIMENTAL
Intervention: In sequence computer tutorial (e.g. FWS patient + FWS tutorial)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Out-of-sequence computer tutorial (e.g. FWS patient + ORS tutorial)
Number of subjects: 92
Study: 20972956

Group type: EXPERIMENTAL
Intervention: Simulator training (group S)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional training only (group C)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups after 60 endoscopic examinations
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups after 10 and 60 endoscopies
Number of subjects: 28
Study: 17118996

Group type: EXPERIMENTAL
Intervention: Iodized salt
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: 400 mg iodine as oral iodized oil
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: 200 mg iodine as oral iodized oil (two doses)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study: 16369066

Group type: COMPARATOR
Intervention: Magnesium
Number of subjects: 39

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 39
Study: 12164886

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination therapy (optimal doses of lisinopril and losartan)
Number of subjects: 9
Study: 10204938

Group type: EXPERIMENTAL
Intervention: 10 mg of morphine (1 ml) and 9 ml of saline
Number of subjects: 437

Group type: COMPARATOR
Intervention: 10 ml of bupivacaine (2.5 mg/ml)
Number of subjects: 437

Group type: COMPARATOR
Intervention: 10 ml of saline
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: 10 mg of morphine (1 ml) and 9 ml of bupivacaine (2.5 mg/ml)
Number of subjects: 437
Study: 7539933

Group type: EXPERIMENTAL
Intervention: Visual aids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no augmented information)
Number of subjects: 0
Study: 2155948

Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: conventional metoprolol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 7006073

Group type: EXPERIMENTAL
Intervention: Vaccinated with intact influenza vaccine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 21
Study: 27406943

Group type: EXPERIMENTAL
Intervention: 500 mL of enteral nutrition formulas (2 different formulas)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 15 g lactulose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alternative fructan assay with additional enzymes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Enzymatic assay for GOS
Number of subjects: 15
Study: 25515208

Group type: EXPERIMENTAL
Intervention: Chymosin added to milk
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo added to milk
Number of subjects: 125
Study: 22921821

Group type: EXPERIMENTAL
Intervention: In-hospital international normalized ratio self-testing instruction
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 21516022

Group type: EXPERIMENTAL
Intervention: IV anti-D (50 μg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: IVIG (0.8 to 1 g/kg)
Number of subjects: 25
Study: 19920236

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d)
Number of subjects: 6837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6837
Study: 16972106

Group type: EXPERIMENTAL
Intervention: d-amphetamine 7.5 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 15 mg/70 kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: d-amphetamine 0 mg/70 kg (placebo)
Number of subjects: 0
Study: 14740785

Group type: EXPERIMENTAL
Intervention: Intranasal hydromorphone hydrochloride after 6 days of fluticasone propionate (treatment C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intranasal hydromorphone hydrochloride without allergic rhinitis treatment (treatment B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous hydromorphone hydrochloride 2.0 mg (treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intranasal treatments (B and C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intranasal hydromorphone hydrochloride
Number of subjects: 12
Study: 11460278

Group type: EXPERIMENTAL
Intervention: Essential oil-containing antiseptic mouthrinse (Listerine Antiseptic)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Negative control rinse
Number of subjects: 34
Study: 9377282

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.05%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Natamycin 5%
Number of subjects: 60
Study: 8463939

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Toothpaste brushing after rinsing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Other commercial rinses
Number of subjects: 12
Study: 3010011

Group type: EXPERIMENTAL
Intervention: Oral nabilone (1 mg 8 hourly)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous metoclopramide (1 mg kg‐1 3 hourly)
Number of subjects: 32
Study: 31741069

Group type: EXPERIMENTAL
Intervention: Self-management system for diabetes developed with User Centered Design Principles
Number of subjects: 20
Study: 29287658

Group type: EXPERIMENTAL
Intervention: AcceleDent Aura appliance
Number of subjects: 40

Group type: COMPARATOR
Intervention: No appliance
Number of subjects: 40
Study: 27220537

Group type: EXPERIMENTAL
Intervention: Heated Humidified High-Flow Nasal Cannula (HHHFNC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 101
Study: 24901089

Group type: EXPERIMENTAL
Intervention: SDF (oat β‐glucan 7.5 g, 500 mL, 500 Kcal)
Number of subjects: 30
Study: 22830971

Group type: EXPERIMENTAL
Intervention: Milled chia seed (25 g/day for 10 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Whole chia seed (25 g/day for 10 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (poppy seed, 25 g/day for 10 weeks)
Number of subjects: 62
Study: 19410693

Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 15

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 15
Study: 17461474

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily) and Domperidone (10 mg three times daily)
Number of subjects: 198
Study: 16036039

Group type: EXPERIMENTAL
Intervention: Statins (3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors)
Number of subjects: 0
Study: 12113287

Group type: EXPERIMENTAL
Intervention: 800 mg/day alpha-tocopherol supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not supplemented)
Number of subjects: 18
Study: 9441572

Group type: COMPARATOR
Intervention: 1-month, full-time rotation in interviewing and related psychosocial topics
Number of subjects: 63
Study: 8088061

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gold Sodium Thiomalate (GST)
Number of subjects: 42
Study: 2800995

Group type: EXPERIMENTAL
Intervention: Ketamine 10 mg.kg‐1 BW and midazolam 0.2 mg.kg‐1 BW for induction with intravenous ketamine for maintenance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketamine 10 mg.kg‐1 BW and midazolam 0.2 mg.kg‐1 BW for induction with halothane for maintenance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Halothane for both induction and maintenance
Number of subjects: 30
Study: 790959

Group type: EXPERIMENTAL
Intervention: Cephalosporin prophylaxis
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 30796528

Group type: EXPERIMENTAL
Intervention: Stepped Collaborative Care Model (SCCM) including group-level interventions (START intervention, Empowerment/Gender-sensitive/Peer to peer) and digital treatment approaches (Smartphone application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 0
Study: 31669971

Group type: EXPERIMENTAL
Intervention: S‐FAIF
Number of subjects: 96

Group type: COMPARATOR
Intervention: SMAPF
Number of subjects: 96
Study: 29199566

Group type: EXPERIMENTAL
Intervention: High-dose supplement (HD) group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-dose supplement (LD) group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (PL) group
Number of subjects: 96
Study: 25458669

Group type: EXPERIMENTAL
Intervention: Diabetes specific formula (Nutren Diabetes, Nestlé Health Science, Switzerland)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric meal (Cornflakes and milk)
Number of subjects: 0
Study: 22276649

Group type: EXPERIMENTAL
Intervention: Conventional resin-based sealant with Er:YAG + AE preparation technique
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hydrophilic sealant
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional resin-based sealant
Number of subjects: 80
Study: 21190996

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Multiagent chemotherapy (CT)
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HiDAC)
Number of subjects: 781
Study: 18036904

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft surgery
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass graft surgery
Number of subjects: 201
Study: 16110019

Group type: EXPERIMENTAL
Intervention: CI-1033 200 mg daily for 21 days in a 28-day cycle
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CI-1033 50 mg daily for 21 days in a 28-day cycle
Number of subjects: 105